SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
Study Details
Study Description
Brief Summary
Phase II: Exploring the efficacy and safety of different doses of SH229 tablets combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets in the treatment of adult patients with chronic hepatitis C for 12 weeks, providing a basis for the design and implementation of phase III clinical trials.
Phase III: Confirmation of the efficacy and safety of SH229 tablets combined with Daclatasvi dihydrochloride (DCV) tablets in the treatment of adult patients with chronic hepatitis C for 12 weeks, providing a sufficient basis for drug registration and clinical use.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
It is estimated that China has a population of over 10 million infected with HCV and also a highly variable HCV genotype geographic distribution. A simple, universal, non-genotype-specific treatment regimen is preferred for anti-HCV treatment in clinical practice and public health. The combination regimen of SH229 and DCV is expected to completely suppress HCV replication in subjects chronically infected with HCV and achieve a sustained virologic response.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SH229/DCV 400mg/60mg HCV GT 1-6 participants were medicated with SH229 tablets 400 mg once daily and DCV tablets 60 mg once daily QD (n=40) for 12weeks |
Drug: SH229 tablets
SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
Other Names:
Drug: Daclatasvir dihydrochloride
Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Other Names:
|
| Experimental: SH229/DCV 600mg/60mg HCV GT 1-6 participants were medicated with SH229 tablets 600 mg once daily and DCV tablets 60 mg once daily (n=40). |
Drug: SH229 tablets
SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
Other Names:
Drug: Daclatasvir dihydrochloride
Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Other Names:
|
| Experimental: SH229/DCV 800mg/60mg HCV GT 1-6 participants were medicated with SH229 tablets 800 mg once daily and DCV tablets 60 mg once daily (n=40). |
Drug: SH229 tablets
SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
Other Names:
Drug: Daclatasvir dihydrochloride
Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Other Names:
|
| Experimental: SH229/DCV HCV GT 1-6 participants were medicated with SH229 tablets 400 mg,600 mg or 800 mg once daily and DCV tablets 60 mg once daily |
Drug: SH229 tablets
SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
Other Names:
Drug: Daclatasvir dihydrochloride
Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Sustained virologic response at 12 weeks after end of treatment (SVR12) [12 weeks after end of treatment]
Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)
Secondary Outcome Measures
- Rapid virologic response at 4 week after initiation of treatment (RVR4) [4 week after initiation of treatment]
Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)
- Rapid virologic response at 12 weeks after initiation of treatment (RVR12) [12 weeks after initiation of treatment]
Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)
- Sustained virologic response at 4 weeks after end of treatment (SVR4) [4 weeks after end of treatment]
Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)
- Sustained virologic response at 24 weeks after end of treatment (SVR24) [24 weeks after end of treatment]
Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)
- Virologic breakthrough [2, 4, 8 and 12 weeks after initiation of treatment]
Percentage of subjects with on-treatment re-detected plasma HCV RNA after HCV RNA below the lower limit of quantitation
- Virologic relapse [4 and 12 weeks after end of treatment]
Percentage of subjects with off-treatment re-detected plasma HCV RNA after end-of-treatment HCV RNA below the lower limit of quantitation
- Antiviral effects of SH229 tablets combined with Daclatasvi dihydrochloride (DCV) tablets , as measured by HCV RNA levels [Up to 36 weeks]
To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Willing and able to provide written informed consent.
-
Subjects should be able to follow the instructions for the study drug and be able to complete screening, on-treatment, and post treatment assessments.
-
Male or female, age above 18 years
-
Body mass index ( BMI ) between 18 and 32 kg/m2 at Screening.
-
Confirmation of chronic HCV infection, which meets one of the following: (a) positive for anti-HCV antibodies, HCV RNA or HCV genotyping results within ≤ 6 months of screening, or (b) liver biopsy ≤ 12 months of screening.
-
HCV RNA above 10^4 IU/mL at Screening by the Central Laboratory.
-
HCV genotype 1, 2, 4, 5, 6, or indeterminate assessed at Screening by the Central Laboratory.
-
Classification as treatment naïve or treatment experienced (approximately 20% of subjects may be treatment experienced):
-
Treatment naïve is defined as having never been exposed to approved or experimental HCV-specific direct-acting antiviral agents ( DAA ) or prior treatment of HCV with interferon either with or without RBV.
-
Treatment experienced is defined as prior treatment failure to a regimen containing IFN-based antiviral (INF-α, β or PEG-IFN ± ribavirin) and met one of the following: (i) Non-Responder: Subject did not achieve undetectable HCV RNA levels while ontreatment,, (ii) Relapse/Breakthrough: Subject achieved undetectable HCV RNA levels duringtreatment but did not achieve SVR, (iii) Terminate the treatment , according to associated-HCV therapy adverse events by subject reported or medical records demonstrated.
- Cirrhosis Determination (approximately 20% of subjects may have cirrhosis)：
- Cirrhosis is defined as any one of the following: (i) Fibroscan with a result of
12.5 kPa within ≤ 6 months of screening, (ii) Liver biopsy showing cirrhosis within ≤ 12 months of screening.
- Absence of cirrhosis is defined as any one of the following:(i) Fibroscan with a result of ≤ 12.5 kPa within ≤ 6 months of screening, (ii) Liver biopsy showing non-cirrhosis within ≤ 12 months of screening.
Exclusion Criteria:
-
Exposure nucleotide analogue including HCV NS3-4A inhibitor, HCV NS5B inhibitor or any HCV NS5A inhibitor before baseline/Day 1.
-
Receive IFN-based antiviral therapy within 6 months prior to baseline/day 1.
-
Oral or injection of RBV within 3 months prior to baseline/Day 1.
-
Systemic use of potent immunomodulators (eg, adrenocortical hormone, thymosin alpha, etc.) for more than 2 weeks prior to baseline/day 1, or expected to be exposed to these agents during the study.
-
Use of amiodarone within 2 months before baseline/day 1.
-
Positive for Hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab) at screening.
-
Evidence of decompensatory liver function, including but not limited to total serum bilirubin (TBIL) above twice of the upper limit of normal (ULN), serum albumin (ALB) below 35 g/L or prothrombin activity (PTA) below 60% confirmed on repeated testing, previous or present history of ascites, upper gastrointestinal bleeding and/or hepatic encephalopathy, or with a liver function reserve of Child-Pugh class B or C.
-
Primary liver cancer confirmed or evidenced by serum alfa-fetoprotein (AFP) above 100 ng/ml or liver imaging study showing suspected nodules.
-
liver disease of a non-HCV etiology (e.g. alcoholic liver disease, nonalcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis, Wilson disease or hemochromatosis, etc.).
-
Subjects has the following laboratory parameters at screening: ALT or AST>10×ULN, WBC < 3×109 /L, ANC< 1.5×109 /L（or < 1.25×109 /L for cirrhotics ), PLT< 50×109 /L, Hb < 100 g/L, INR > 1.5×ULN, CLcr < 50 mL/min（calculated by the Cockcroft-Gault equation ）.
-
Uncontrolled diabetes mellitus (HbA1c > 8.0% at screening).
-
Uncontrolled hyperthyroidism or diminished.
-
Psychiatric or neurologic disorders, including previous or family history of psychiatric disorders (especially depression, depressive state, epilepsy or hysteria).
-
Serious cardiovascular disorders, including uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥100 mmHg), heart insufficiency of New York Heart Association class III or above, history of myocardial infarction within 6 months before the screening, history of percutaneous transluminal coronary angioplasty within 6 months before the screening, unstable angina pectoris, or QTc interval (Fridericia correction formula QTc = QT×RR^-1/3) at or above 450 mse, second- or third-grade atrioventricular block or any other uncontrolled arrhythmias confirmed on repeated electrocardiography on screening.
-
Serious hematologic disorders (e.g. anemia, hemophilia, etc.).
-
Serious kidney diseases (e.g. chronic kidney disease, kidney insufficiency, etc.).
-
Serious gastrointestinal disorders, (e.g. peptic ulcer, colitis, etc.) or post operative condition that could interfere with the absorption of the study drug.
-
Serious respirator disorders, (e.g. active pulmonary tuberculosis, lung infection, chronic obstructive pulmonary disease, pulmonary interstitial disease, etc.).
-
Malignancy within the 5 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc).
-
Solid organ transplantation.
-
Hypersensitive predisposition or a known history of serious allergy, especially to the investigational products and substances.
-
Positive urine drug screening at screening, or Clinically-relevant alcohol or drug abuse within 12 months of screening, and compliance and effectiveness evaluated by the investigator.
-
Positive screening serum pregnancy test or baseline/day 1 serum or urine pregnancy test, and women are confirmed in pregnancy or lactation.
-
Women of childbearing age (menopausal women aged ≤ 50 years old are also considered to have fertility), or partners who are women of childbearing age cannot comply with voluntary effective contraceptive measures during the 6 months from screening to the last dose of test drug.
-
Use of any prohibited concomitant medications as described in protocol.
-
Participated in clinical studies or previously participated within 3 months prior to baseline/Day 1.
-
Conditions which investigator judges that it is not suitable for enrollment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Hospital of Jilin University | Jilin | Jiangsu | China | 130021 |
Sponsors and Collaborators
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Investigators
- Principal Investigator: Junqi Niu, Ph.D, The First Hospital of Jilin University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SHC005-II/III-01